TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7134858

Group type: EXPERIMENTAL
Intervention: Resection combined with conversion to an end‐to‐end anastomosis (Scott)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Simple resection of the elongated segment of the shunt
Number of subjects: 16
Study: 31910459

Group type: EXPERIMENTAL
Intervention: Patients with Borderline Personality Disorder (BPD)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Patients with depressive disorder
Number of subjects: 37
Study: 30306831

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for 8 weeks
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for 8 weeks (responders)
Number of subjects: 25
Study: 29084595

Group type: EXPERIMENTAL
Intervention: Shared care model involving replacement of two routine specialist follow‐up visits with PCP visits, provision of a tailored survivorship care plan, and a survivorship booklet and DVD for CRC survivors.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study: 25800376

Group type: EXPERIMENTAL
Intervention: Surgical treatment of hip fractures in patients with Parkinson's disease
Number of subjects: 141

Group type: COMPARATOR
Intervention: Surgical treatment of hip fractures in patients without Parkinson's disease (Control)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Reoperation for displaced and nondisplaced fractures in patients with Parkinson's disease
Number of subjects: 141

Group type: COMPARATOR
Intervention: Reoperation for displaced and nondisplaced fractures in patients without Parkinson's disease (Control)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Internal fixation for nondisplaced femoral neck fractures in patients with Parkinson's disease
Number of subjects: 141

Group type: COMPARATOR
Intervention: Internal fixation for nondisplaced femoral neck fractures in patients without Parkinson's disease (Control)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty for displaced femoral neck fractures in patients with Parkinson's disease
Number of subjects: 141

Group type: COMPARATOR
Intervention: Hemiarthroplasty for displaced femoral neck fractures in patients without Parkinson's disease (Control)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty through an anterolateral approach
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty through a posterior approach
Number of subjects: 141
Study: 24898622

Group type: EXPERIMENTAL
Intervention: Topical ivermectin (1% applied to affected skin, 400 μg/kg, repeated once the following week)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Crotamiton cream 10% (applied twice daily for five consecutive days)
Number of subjects: 340
Study: 21696902

Group type: EXPERIMENTAL
Intervention: Morphine sulfate (n=20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (n=20 patients; control group)
Number of subjects: 40
Study: 19390585

Group type: EXPERIMENTAL
Intervention: AMA-1/AS01B (50 microg/0.5 mL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMA-1/AS02A (50 microg/0.5 mL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMA-1/AS01B (10 microg/0.5 mL)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMA-1/AS02A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (malaria challenge with P. falciparum-infected mosquitoes)
Number of subjects: 30
Study: 17531696

Group type: EXPERIMENTAL
Intervention: Coaxial phacoemulsification
Number of subjects: 30

Group type: COMPARATOR
Intervention: Microincision cataract surgery (MICS)
Number of subjects: 30
Study: 15298068

Group type: EXPERIMENTAL
Intervention: Sublingually administered cannabis extracts containing approximately equal concentrations of delta9-THC and cannabidiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delta9-tetrahydrocannabinol (delta9-THC)
Number of subjects: 0
Study: 11313175

Group type: EXPERIMENTAL
Intervention: CAELYX (50 mg/m² by a 1 h intravenous infusion every 4 weeks)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Doxorubicin (75 mg/m² by an intravenous bolus every 3 weeks)
Number of subjects: 94
Study: 9392331

Group type: EXPERIMENTAL
Intervention: Mammographic screening every 18 months using two-view mammography
Number of subjects: 11724

Group type: EXPERIMENTAL
Intervention: Mammographic screening with conservative estimate removing tumors detected at first screen of control group
Number of subjects: 11724

Group type: COMPARATOR
Intervention: Control group (not invited to screening until the fifth screen)
Number of subjects: 11724
Study: 8179235

Group type: EXPERIMENTAL
Intervention: Multiple item elimination diet
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 3131387

Group type: EXPERIMENTAL
Intervention: Pure FSH (A1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of LHRH agonist and pure FSH (A2)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (B)
Number of subjects: 16
Study: 31914967

Group type: EXPERIMENTAL
Intervention: Community-based, gender-sensitive and culturally adapted brief counselling intervention (SIRIAN program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 0
Study: 31928038

Group type: EXPERIMENTAL
Intervention: Stimulation of positive emotions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative emotions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orosensory stimulation via sweet taste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 28124506

Group type: EXPERIMENTAL
Intervention: Liraglutide up to 1.8 mg s.c. once daily
Number of subjects: 95

Group type: COMPARATOR
Intervention: Metformin up to 1,000 mg twice daily
Number of subjects: 95
Study: 25922119

Group type: EXPERIMENTAL
Intervention: MLP using 16 clinical variables
Number of subjects: 1924
Study: 24069472

Group type: EXPERIMENTAL
Intervention: Benznidazole treatment with weekly evaluations
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Benznidazole treatment with twice-weekly evaluations
Number of subjects: 162

Group type: COMPARATOR
Intervention: Benznidazole treatment with historical controls
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Benznidazole treatment with prospective patients
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Benznidazole treatment
Number of subjects: 162
Study: 21848444

Group type: EXPERIMENTAL
Intervention: Intensive-counselling group (n = 61)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Brief-counselling group (n = 59)
Number of subjects: 120
Study: 20166438

Group type: EXPERIMENTAL
Intervention: Single dose of 40, 80, and 120 mg intramuscular tramadol hydrochloride injection
Number of subjects: 0
Study: 17266689

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg per day for 4 weeks followed by peg‐IFN 1.0 mug/kg/wk for 24 weeks (Group B)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo for 4 weeks followed by peg‐IFN 1.0 mug/kg/wk for 24 weeks (Group A)
Number of subjects: 63
Study: 15519189

Group type: EXPERIMENTAL
Intervention: PDE III inhibitor (PDE III‐I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Papaverine hydrochloride
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 80
Study: 12521457

Group type: EXPERIMENTAL
Intervention: Push method
Number of subjects: 108

Group type: COMPARATOR
Intervention: Pull (reverse breech) method
Number of subjects: 108
Study: 9890717

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (NovoSeven) at doses of 5, 10, 20, 40, 80, 120, 160, 240, or 320 microg/kg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIa (NovoSeven)
Number of subjects: 28
Study: 8017663

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pressure-Controlled Ventilation (PCV) with conventional ratio (I:E 1:2; PC 1/2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Pressure-Controlled Inverse Ratio Ventilation (PCIRV) (I:E 2:1 and 3:1; PC 2/1 and PC 3/1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PC 2/1
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: PC 3/1
Number of subjects: 9
Study: 2810454

Group type: EXPERIMENTAL
Intervention: Clemastine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30628552

Group type: EXPERIMENTAL
Intervention: Art therapy activities (12 artistic activities)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Ordinary activities
Number of subjects: 55
Study: 28125513

Group type: EXPERIMENTAL
Intervention: DC vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 25753493

Group type: EXPERIMENTAL
Intervention: 600 mg of alpha-lipoic acid (ALA) supplementation for 12 weeks
Number of subjects: 58
Study: 23877706

Group type: EXPERIMENTAL
Intervention: Faldaprevir monotherapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Faldaprevir-PegIFN-RBV triple therapy
Number of subjects: 88
Study: 21883124

Group type: EXPERIMENTAL
Intervention: Desmopressin 1.5 μg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Desmopressin 5 μg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Desmopressin 15 μg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 52
Study: 19787539

Group type: EXPERIMENTAL
Intervention: External focus of attention (focusing on surroundings)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internal focus of attention (focusing on running movement and breathing)
Number of subjects: 0
Study: 17940987

Group type: EXPERIMENTAL
Intervention: DHEA therapy (150 mg oral daily for 40 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 14704629

Group type: EXPERIMENTAL
Intervention: Vitrolife
Number of subjects: 176

Group type: COMPARATOR
Intervention: MediCult
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Vitrolife (ICSI cycles)
Number of subjects: 176
Study: 11171607

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Protein-free fast
Number of subjects: 9
Study: 9762002

Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg/day of hGH for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Combined lower dose group (0.05 or 0.1 IU/kg/day of hGH for 7 days)
Number of subjects: 16
Study: 7852551

Group type: EXPERIMENTAL
Intervention: Prophylaxis with ganciclovir for 2 weeks and then high-dose acyclovir for 2.5 months
Number of subjects: 3552

Group type: COMPARATOR
Intervention: High-dose acyclovir alone for 3 months
Number of subjects: 3552

Group type: EXPERIMENTAL
Intervention: Asymptomatic CMV infections
Number of subjects: 3552

Group type: EXPERIMENTAL
Intervention: Symptomatic CMV infections
Number of subjects: 3552
Study: 2691482

Group type: EXPERIMENTAL
Intervention: amoxycillin/clavulanate
Number of subjects: 141

Group type: COMPARATOR
Intervention: cefoxitin
Number of subjects: 141
Study: 1183220

Group type: EXPERIMENTAL
Intervention: Gaviscon
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (antacid containing)
Number of subjects: 26
Study: 31838759

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 344
Study: 31240310

Group type: EXPERIMENTAL
Intervention: Lapatinib and/or Trastuzumab
Number of subjects: 8381
Study: 27981455

Group type: EXPERIMENTAL
Intervention: Virtual walking integrated physiotherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Traditional physiotherapy (control group)
Number of subjects: 44
Study: 25617251

Group type: EXPERIMENTAL
Intervention: Family-centered foster care (FCG)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Care-as-usual group (CAUG)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Never-Institutionalized group (NIG)
Number of subjects: 117
Study: 24200413

Group type: EXPERIMENTAL
Intervention: Spinal fusion (instrumented or noninstrumented fusion, stabilization)
Number of subjects: 473

Group type: COMPARATOR
Intervention: Multidisciplinary cognitive-behavioral and exercise rehabilitation
Number of subjects: 473
Study: 21532506

Group type: EXPERIMENTAL
Intervention: C/P/T (Carboplatin and Paclitaxel plus Talactoferrin)
Number of subjects: 110

Group type: COMPARATOR
Intervention: C/P/P (Carboplatin and Paclitaxel plus Placebo)
Number of subjects: 110
Study: 18165598

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine + rofecoxib 50 mg
Number of subjects: 114

Group type: COMPARATOR
Intervention: 0.5% bupivacaine + placebo
Number of subjects: 114

Group type: COMPARATOR
Intervention: 2% lidocaine + placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 2% lidocaine + rofecoxib 50 mg
Number of subjects: 114
Study: 16861092

Group type: EXPERIMENTAL
Intervention: Fentanyl effervescent buccal tablet (FEBT) 100 microg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fentanyl effervescent buccal tablet (FEBT) 200 microg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fentanyl effervescent buccal tablet (FEBT) 400 microg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fentanyl effervescent buccal tablet (FEBT) 800 microg
Number of subjects: 32
Study: 15733521

Group type: EXPERIMENTAL
Intervention: Isosmotic polyethylene glycol 3350 electrolyte solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isosmotic electrolyte solution
Number of subjects: 12
Study: 12928729

Group type: EXPERIMENTAL
Intervention: Clinical pathway (path group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Traditional practice (control group)
Number of subjects: 87
Study: 10362377

Group type: COMPARATOR
Intervention: Platelet aggregability studies on day 1 after pacemaker implantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Platelet aggregability studies on day 3 after pacemaker implantation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Platelet aggregability studies on day 30 after pacemaker implantation
Number of subjects: 20
Study: 7745051

Group type: EXPERIMENTAL
Intervention: Embryo transfer on day 3 post-insemination
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Embryo transfer on day 2 post-insemination
Number of subjects: 1228
Study: 2292629

Group type: EXPERIMENTAL
Intervention: Stress inoculation program
Number of subjects: 72

Group type: COMPARATOR
Intervention: Child-focused intervention program
Number of subjects: 72
Study: 7288563

Group type: EXPERIMENTAL
Intervention: Misattribution treatment (high-frequency noise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (shy women expecting shyness-irrelevant side effects)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not-shy women)
Number of subjects: 0
Study: 31744705

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AuraGain
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: iLTS-D
Number of subjects: 30
Study: 28763243

Group type: EXPERIMENTAL
Intervention: FS MDPI 50/12.5 mcg
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: FS MDPI 100/12.5 mcg
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Fp MDPI 50 mcg
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Fp MDPI 100 mcg
Number of subjects: 640

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study: 28850523

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 34
Study: 24977321

Group type: EXPERIMENTAL
Intervention: Ultrasound guided ureteroscopy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluoroscopic guided ureteroscopy
Number of subjects: 50
Study: 22017530

Group type: EXPERIMENTAL
Intervention: Y1 antagonist (AR-H040922) during atenolol
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Y1 antagonist (AR-H040922) during metoprolol
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo phase (metoprolol)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo phase (atenolol)
Number of subjects: 71
Study: 21111318

Group type: EXPERIMENTAL
Intervention: Gas-forced infusion (air pump)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no gas-forced infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 19014792

Group type: EXPERIMENTAL
Intervention: PATH Woman's Condom (WC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: FC1 Female Condom (FC1)
Number of subjects: 75
Study: 16802774

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 200 microg daily
Number of subjects: 736

Group type: COMPARATOR
Intervention: Montelukast, 10 mg daily
Number of subjects: 736
Study: 12706276

Group type: EXPERIMENTAL
Intervention: Amnioinfusion with warmed normal saline
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no amnioinfusion)
Number of subjects: 160
Study: 12594897

Group type: EXPERIMENTAL
Intervention: Acylaminopenicillin-based therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cephalosporin-based antibiotic therapy
Number of subjects: 110
Study: 8722604

Group type: EXPERIMENTAL
Intervention: Zinc acetate with erythromycin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Erythromycin without zinc acetate
Number of subjects: 12
Study: 1571637

Group type: EXPERIMENTAL
Intervention: Transurethral prostatectomy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control procedures (herniorrhaphy and testicular exploration)
Number of subjects: 33
Study: 6536768

Group type: EXPERIMENTAL
Intervention: Grief group therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30521663

Group type: EXPERIMENTAL
Intervention: Peer-mediated approach and speech-generating device
Number of subjects: 45

Group type: COMPARATOR
Intervention: Business-as-usual condition with untrained peers
Number of subjects: 45
Study: 30420116

Group type: EXPERIMENTAL
Intervention: BRV-PV (Lot A, B, C)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: BRV-PV
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Rotarix®
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: BRV-PV, Rotarix®
Number of subjects: 1500
Study: 26948468

Group type: COMPARATOR
Intervention: Physical activity intervention (brisk walking)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutritional intervention (lycopene supplementation or increased fruit and vegetables with reduced dairy consumption)
Number of subjects: 0
Study: 24762259

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (6-months treatment)
Number of subjects: 60
Study: 22534580

Group type: EXPERIMENTAL
Intervention: Imagined non-consensual kiss from a physically dirty man
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Imagined consensual kiss from a physically clean man
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Imagined consensual kiss from a physically dirty man
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Imagined non-consensual kiss from a physically clean man
Number of subjects: 140
Study: 20925996

Group type: EXPERIMENTAL
Intervention: Prenatal contraceptive counselling
Number of subjects: 180

Group type: COMPARATOR
Intervention: Educational leaflet (Control)
Number of subjects: 180
Study: 17949786

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: False-positive cases (CD3(+) and CD5(+) T cells)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Negative post-rituximab bone marrow
Number of subjects: 39
Study: 16097553

Group type: EXPERIMENTAL
Intervention: TKA with relatively flat or concave tibial insert (retaining posterior cruciate ligament)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: TKA with concave or posterior-stabilized tibial component (resecting posterior cruciate ligament)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study: 12794096

Group type: COMPARATOR
Intervention: Walking at 0.5-1.5 m/s with loads of 0, 10, 20, and 30% body mass
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Walking at speeds of 1.5-2.0 m/s
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cost of generating force per unit volume of active muscle (k) across all conditions
Number of subjects: 8
Study: 10852048

Group type: EXPERIMENTAL
Intervention: New concentrated inactivated leptospirosis vaccine (0.5 ml, single injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing commercial vaccine (2.0 ml and 2.5 ml, two injections)
Number of subjects: 0
Study: 7491373

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 1710591

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl-starch (250 ml daily) + Pentoxifylline (oral: 1200 mg/day; i.v.: 300 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no hemodilution or rheological therapy)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl-starch + Pentoxifylline
Number of subjects: 40
Study: 6955502

Group type: EXPERIMENTAL
Intervention: Butler waxed dental floss
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Butler unwaxed dental floss
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Johnson and Johnson waxed dental floss
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Johnson and Johnson unwaxed dental floss
Number of subjects: 80
Study: 30292760

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 0
Study: 29155035

Group type: EXPERIMENTAL
Intervention: 20 mL 0.25% bupivacaine (treatment group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: 20 mL normal saline solution (control group)
Number of subjects: 84
Study: 27267310

Group type: EXPERIMENTAL
Intervention: Personalized, body‐worn hand hygiene system
Number of subjects: 3256

Group type: COMPARATOR
Intervention: Usual intraoperative hand hygiene (control)
Number of subjects: 3256
Study: 24603631

Group type: EXPERIMENTAL
Intervention: Individualized frequency whole body vibration (WBV) for three 4-minute sessions
Number of subjects: 18